Katherine A. Stueland's most recent trade in GeneDx Holdings Corp - Ordinary Shares - Class A was a trade of 3,220 Class A Common Stock done at an average price of $93 . Disclosure was reported to the exchange on July 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 93.00 per share. | 09 Jul 2025 | 3,220 | 1,720 | - | 93 | 299,460 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 90.68 per share. | 01 Jul 2025 | 6,928 | 7,669 | - | 90.7 | 628,215 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Stueland Katherine A. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 91.55 per share. | 01 Jul 2025 | 2,594 | 5,075 | - | 91.6 | 237,483 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Stueland A. Katherine | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 92.46 per share. | 01 Jul 2025 | 135 | 4,940 | - | 92.5 | 12,482 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 18,750 | 131,250 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 18,750 | 25,098 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 64.77 per share. | 16 Jun 2025 | 10,501 | 14,597 | - | 64.8 | 680,181 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 6,547 | 9,987 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 6,547 | 39,279 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.55 per share. | 09 Jun 2025 | 3,639 | 6,348 | - | 72.5 | 264,009 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 3,874 | 5,594 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2025 | 3,874 | 15,496 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 113.09 per share. | 29 Apr 2025 | 2,154 | 3,440 | - | 113.1 | 243,596 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 93.33 per share. | 09 Apr 2025 | 9,628 | 13,283 | - | 93.3 | 898,558 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 86.34 per share. | 09 Apr 2025 | 5,855 | 28,084 | - | 86.3 | 505,549 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 94.55 per share. | 09 Apr 2025 | 4,511 | 8,772 | - | 94.6 | 426,517 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 83.25 per share. | 09 Apr 2025 | 3,297 | 39,859 | - | 83.3 | 274,486 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 85.44 per share. | 09 Apr 2025 | 3,175 | 33,939 | - | 85.4 | 271,262 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 96.29 per share. | 09 Apr 2025 | 3,174 | 2,425 | - | 96.3 | 305,637 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 95.51 per share. | 09 Apr 2025 | 3,173 | 5,599 | - | 95.5 | 303,053 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 82.17 per share. | 09 Apr 2025 | 3,134 | 43,156 | - | 82.2 | 257,509 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 84.28 per share. | 09 Apr 2025 | 2,745 | 37,114 | - | 84.3 | 231,348 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 81.16 per share. | 09 Apr 2025 | 2,024 | 46,290 | - | 81.2 | 164,262 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 91.27 per share. | 09 Apr 2025 | 1,900 | 23,911 | - | 91.3 | 173,420 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 90.13 per share. | 09 Apr 2025 | 1,600 | 25,811 | - | 90.1 | 144,207 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 92.28 per share. | 09 Apr 2025 | 1,000 | 22,911 | - | 92.3 | 92,280 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 97.24 per share. | 09 Apr 2025 | 705 | 1,720 | - | 97.2 | 68,557 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 87.30 per share. | 09 Apr 2025 | 373 | 27,711 | - | 87.3 | 32,563 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 88.70 per share. | 09 Apr 2025 | 300 | 27,411 | - | 88.7 | 26,609 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 80,000 | 94,865 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 80,000 | 240,000 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 95.66 per share. | 26 Mar 2025 | 44,801 | 50,064 | - | 95.7 | 4,285,561 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 94.59 per share. | 26 Mar 2025 | 1,750 | 48,314 | - | 94.6 | 165,524 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2025 | 6,546 | 45,826 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2025 | 6,546 | 10,483 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 94.73 per share. | 09 Mar 2025 | 2,731 | 7,752 | - | 94.7 | 258,695 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2025 | 3,874 | 19,370 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2025 | 3,874 | 5,594 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 78.48 per share. | 29 Jan 2025 | 1,657 | 3,937 | - | 78.5 | 130,046 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 93.34 per share. | 07 Jan 2025 | 23,800 | 29,340 | - | 93.3 | 2,221,442 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 96.39 per share. | 07 Jan 2025 | 10,005 | 1,720 | - | 96.4 | 964,359 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 95.50 per share. | 07 Jan 2025 | 9,176 | 11,725 | - | 95.5 | 876,282 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 94.33 per share. | 07 Jan 2025 | 8,439 | 20,901 | - | 94.3 | 796,036 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 79.68 per share. | 02 Jan 2025 | 4,242 | 54,704 | - | 79.7 | 337,991 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 78.58 per share. | 02 Jan 2025 | 4,078 | 58,946 | - | 78.6 | 320,433 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 77.88 per share. | 02 Jan 2025 | 3,417 | 63,024 | - | 77.9 | 266,120 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.47 per share. | 02 Jan 2025 | 2,654 | 68,492 | - | 75.5 | 200,307 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 76.54 per share. | 02 Jan 2025 | 2,051 | 66,441 | - | 76.5 | 156,976 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 80.47 per share. | 02 Jan 2025 | 1,564 | 53,140 | - | 80.5 | 125,860 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Stueland A. Katherine | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 18,750 | 81,647 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 18,750 | 168,750 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine Stueland A. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 76.75 per share. | 16 Dec 2024 | 10,501 | 71,146 | - | 76.8 | 805,995 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 6,547 | 52,372 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 6,547 | 66,558 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 76.37 per share. | 09 Dec 2024 | 3,661 | 62,897 | - | 76.4 | 279,598 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.91 per share. | 15 Nov 2024 | 8,580 | 63,142 | - | 70.9 | 608,418 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.72 per share. | 15 Nov 2024 | 7,240 | 87,889 | - | 70.7 | 511,985 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.15 per share. | 15 Nov 2024 | 6,186 | 71,722 | - | 70.2 | 433,952 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.65 per share. | 15 Nov 2024 | 5,497 | 99,929 | - | 68.7 | 377,386 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.67 per share. | 15 Nov 2024 | 4,800 | 95,129 | - | 69.7 | 334,439 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.98 per share. | 15 Nov 2024 | 3,151 | 77,908 | - | 69.0 | 217,349 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.83 per share. | 15 Nov 2024 | 3,131 | 60,011 | - | 71.8 | 224,905 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.95 per share. | 15 Nov 2024 | 2,043 | 83,888 | - | 73.0 | 149,045 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.49 per share. | 15 Nov 2024 | 1,958 | 85,931 | - | 71.5 | 139,977 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 73.71 per share. | 15 Nov 2024 | 1,510 | 82,378 | - | 73.7 | 111,302 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 66.60 per share. | 15 Nov 2024 | 800 | 81,518 | - | 66.6 | 53,283 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.94 per share. | 15 Nov 2024 | 459 | 81,059 | - | 67.9 | 31,183 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.33 per share. | 15 Nov 2024 | 60 | 82,318 | - | 74.3 | 4,460 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2024 | 3,874 | 107,580 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2024 | 3,874 | 23,244 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 66.60 per share. | 29 Oct 2024 | 2,154 | 105,426 | - | 66.6 | 143,456 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 18,750 | 114,207 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 18,750 | 187,500 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 37.59 per share. | 16 Sep 2024 | 10,501 | 103,706 | - | 37.6 | 394,733 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 6,546 | 99,096 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 6,546 | 58,919 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.33 per share. | 09 Sep 2024 | 3,639 | 95,457 | - | 33.3 | 121,288 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2024 | 3,874 | 94,704 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2024 | 3,874 | 27,118 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.54 per share. | 29 Jul 2024 | 2,154 | 92,550 | - | 33.5 | 72,245 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 18,750 | 206,250 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 18,750 | 98,513 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.31 per share. | 16 Jun 2024 | 7,683 | 90,830 | - | 28.3 | 217,506 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2024 | 6,546 | 82,415 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2024 | 6,546 | 65,465 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 24.92 per share. | 09 Jun 2024 | 2,652 | 79,763 | - | 24.9 | 66,088 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2024 | 15,496 | 30,992 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2024 | 15,496 | 82,194 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 11.04 per share. | 29 Apr 2024 | 6,325 | 75,869 | - | 11.0 | 69,808 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 320,000 | 320,000 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 47,684 | 47,684 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 18,750 | 150,000 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 18,750 | 25,424 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 96.71 per share. | 26 Mar 2024 | 10,559 | 14,865 | - | 96.7 | 1,021,146 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 89.44 per share. | 26 Mar 2024 | 1,078 | 6,674 | - | 89.4 | 96,420 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2024 | 18,750 | 225,000 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2024 | 18,750 | 75,257 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 10.59 per share. | 16 Mar 2024 | 8,559 | 66,698 | - | 10.6 | 90,661 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 9.21 per share. | 12 Mar 2024 | 2,618 | 56,507 | - | 9.2 | 24,111 | Class A Common Stock |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2024 | 6,547 | 59,125 | - | 0 | Class A Common Stock | |
| GeneDx Holdings Corp - Ord... | Katherine A. Stueland | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2024 | 6,547 | 72,011 | - | - | Restricted Stock Unit |